

Index

Italicized Page numbers refer to tables

A

- ABCA1, *see* Adenosine triphosphate-binding cassette protein A1 (ABCA1)
- Abdominal adiposity, 39
- ACSM's Guidelines for Exercise Testing and Prescription*, 120
- Acute *vs.* chronic effect of exercise, 117
- Adenosine triphosphate-binding cassette protein A1 (ABCA1), 157, 216
- Adherence LDL-lowering, interventions to improve, 35
- Adults below 35 years, hyperlipidemia prevention, 172–173
- Adult Treatment Panel III (ATP III), 15, 21–37, 73, 172, 178, 179, 195
 - new features, 19
 - normal lipid values, 19
- Agents, effects/dosage/usage (drug treatment)
 - absorption inhibitors, 136
 - combination agents, 141–142
 - more than two, 143–144
 - fibrate, 138
 - fibrates plus niacin, 143–144
 - fish oil, 140–141
 - niacin, 137–138
 - resins/bile acid sequestrants, 134–136
 - statins, 138–140
 - used in combination
 - fibrates plus niacin, 143–144
 - resins plus fibrates, 143
 - resins plus niacin, 143
 - statin combinations, 143
- AHA, *see* American Heart Association (AHA)
- ALE, *see* Artichoke leaf extract (ALE)
- Allium sativum*, *see* Garlic, studies on
- American Academy of Family Physicians (AAFP), 126
- American Heart Association (AHA), 51, 174, 185, 190
- The American Heart Association and the American College of Cardiology (AHA/ACC), guidelines for prevention, 11
- American heart association diet and lifestyle recommendations revision 2006, 58
 - goals, 59–60
 - specific dietary recommendations, 60–62
- Americans In Motion (AIM), 126
 - patient counseling, implementation of AIM program, 126–127
 - program summary, 127
- Apolipoprotein A-1, 188
 - See also* Tools, risk assessment
- Apolipoprotein B, 188
 - See also* Tools, risk assessment
- Artichoke, 100
 - See also* Therapeutic foods
- Artichoke leaf extract (ALE), 100
- ASCVD, *see* Atherosclerotic Cardiovascular Disease (ASCVD)
- Aspirin prophylaxis, 185–186
- Aspirin use (daily), benefits and harms, 186
- ASPVD, *see* Atherosclerotic Peripheral Disease (ASPVD)
- Atherosclerosis, age of start
 - Bogalusa Heart Study, 2
 - Muscatine Study, 2
 - PDAY, 2
- Atherosclerotic cardiovascular disease (ASCVD), 113, 172, 179–180
- Atherosclerotic Peripheral Disease (ASPVD), 179, 180
- Atkins, Dr. Robert, 40

- Atkins Diet, 40–41
 comparative studies, 46
See also Dietary interventions
- ATP III, *see* Adult Treatment Panel III (ATP III)
- ATP III/II, shared features, 18
- B**
- Ballistic stretching, 124
- Basil
 adaptogen, 102
See also Therapeutic foods
- Beers criteria, 164
See also Elderly, hyperlipidemia prevention in
- BMI, body mass index, 1, 2, 43, 44, 46, 48, 49, 59, 66, 87, 162, 172, 173, 218
- BNP, *see* B-Type Natriuretic Peptide (BNP)
- Bogalusa Heart Study, 2
- Borg's Perceived Exertion and Pain Scales*, 122
- B-Type Natriuretic Peptide (BNP), 189
See also Tools, risk assessment
- C**
- Cardiorespiratory exercise, 118, 122–123
 prescription
 initial conditioning, 122
 maintenance, 123
See also Exercise prescriptions
- Cardiovascular disease (CVD), 91, 113, 174
- Cardiovascular risk factor interventions in women, 171
- CARE-1996, *see* Cholesterol and Recurrent Events trial
- Carotid Intimal Thickness (IMT), 190
See also Tools, risk assessment
- Carotid intima medial thickness (IMT)
 prediction in adults, 2
- Cases
 children, 208–209
 healthy young adult with high-risk family history, 203–204
 high LDL, but cannot use statins, 211–213
 high triglycerides/low HDL and metabolic syndrome, 210–211
 patient at intermediate risk, 206–207
 patient with type 2 diabetes mellitus, 204–206
 very low goal LDL cholesterol, 207–208
 well elderly patient, 201–203
- Center for Food and Drug Interaction, 155
- CETP, *see* Cholesterol ester transferase protein (CETP)
- Children, hyperlipidemia prevention, 173–174
 AHA guidelines, prevention of atherosclerosis, 174
 guideline on lipids, NCEP, 173
See also Special population, hyperlipidemia prevention
- Chocolate
 flavonoids, sources, 85
 studies, 85
 stearic acid, studies on, 85–86
See also Therapeutic foods
- Cholesterol and Recurrent Events Trial, 5
- Cholesterol ester transferase protein (CETP), 156
- Cholesterol Lowering Atherosclerosis Study (CLAS), 2
- Cocoa, *see* Flavonoids; Therapeutic foods
- Coenzyme Q10, 96
See also Therapeutic foods
- Colestipol, 2, 134, 135, 136
Commiphora mukul, *see* Myrrh
- Coronary artery disease (CAD), 3, 77, 115, 166, 199
- Coronary artery risk factors
 high blood pressure, 2
 high body mass index (BMI), 2
 high LDL, 2
 low HDL (high density lipoprotein), 2
- Coronary calcium score, interpretation of, 189
- Coronary heart disease (CHD), major
 primary prevention trials of statin treatment, 4
- C-reactive protein, 46, 49, 50, 171, 186, 197
Cynara scolymus, *see* Artichoke
- D**
- DART, *see* Diet and Reinfarction Trial (DART)
- DASH diet, 58
- Dementia patients
 (Alzheimer's/vascular/mixed dementia), hyperlipidemia prevention
 with chronic infectious disease, 180, 181
 with chronic obstructive pulmonary disease (COPD), 180
 with diabetes, 180–181
 frail patient, 182
 with liver disease, 181–182
 with renal disease, 181
See also Special population, hyperlipidemia prevention
- DHA, *see* Docosahexaenoic acid (DHA)
- Diet and Reinfarction Trial (DART), 77

- Dietary Approaches to Stop Hypertension Eating Plan (DASH), *see* DASH diet
 - Dietary components of diets, 63
 - Dietary interventions
 - Atkins diet, 40–41
 - low-carbohydrate, *see* Low-carbohydrate diets
 - Mediterranean, *see* Mediterranean diet
 - NCEP/TLC/AHA, *see* NCEP/TLC/AHA dietary guidelines
 - from NCEP to TLC, *see* NCEP to TLC
 - special populations, for
 - summary recommendations, 62–66
 - Dietary interventions and lipid parameters, 40
 - Docosahexaenoic acid (DHA), 75
 - Drug interactions (safety/tolerability/severe side effects), 144–150
 - absorption inhibitors, 155
 - bile acid sequestrants, 154
 - drug-food side effects
 - grapefruit juice and hyperlipidemia therapy, 155–156
 - fibrates, 154
 - myalgias, 144
 - niacin, 154–155
 - extended-release, 137, 155
 - NINDS, 144
 - statins, 153–154
 - hepatic toxicity, 153
 - polypharmacy, 153
 - Drugs, future
 - agents with multiple actions, 157
 - muraglitazar, 157
 - thiazolidinedione agents, 157
 - cannabinoid-1 receptor antagonists, 157
 - RIO trials, 157
 - greater HDL elevation, 156–157
 - ABCA1 promoters, 157
 - CETP, inhibition of, 156
 - hepatic lipase inhibitors, 157
 - lecithin cholesterol acyltransferase (LCAT) promoters, 157
 - lipoprotein lipase promoters, 157
 - scavenger receptor class-B1 protein inhibitors (SR-B1), 157
 - greater LDL reduction, 156
 - immunosuppression to reduce atherosclerosis, 157–158
 - Drug therapy for patients and high/low lipid abnormality, 198
 - Drug tolerability and potentially severe side effects, 151
 - Drug treatment, 133
 - agents, 133
 - agents used in combination
 - resins plus fibrates, 143
 - statin combinations, 143
 - hyperlipidemia, principles of, 131
 - Dyslipidemia
 - endstate exercise prescription, 125
 - secondary causes, 199
- E**
- EBCT, *see* Electron Beam Computed Tomography (EBCT)
 - Eggplant, 101
 - See also* Therapeutic foods
 - Eicosapentaenoic acid (EPA), 75
 - Elderly, hyperlipidemia prevention in, 163
 - geriatric prescribing, principles of, 164–165
 - ten steps, 164
 - healthy people 2010, 161–162
 - hypercholesterolemia and oldest-old (above 85), 163–164
 - liver function, 163
 - normal physiological aging, 162–163
 - prevention strategies, *see* Prevention strategies (hyperlipidemia) in elderly
 - renal function, 162–163
 - treatment risk paradox, 165
 - “conservative hands-off approach,” 165
 - See also* Special population, hyperlipidemia prevention
 - Electron Beam Computed Tomography (EBCT), 189–190
 - Elite athletes, hyperlipidemia prevention in
 - anabolic steroids on lipids, effect of, 176
 - definition, 175
 - detraining effects, 177–178
 - with dyslipidemia, treatment of, 177
 - female athlete triad, 176–177
 - triad, definition, 177
 - female elite athletes, 176
 - lipid subfractions, 175–176
 - See also* Special population, hyperlipidemia prevention
 - Endurance sports, 114–115
 - Enhancing Adherence, Clinician’s Abridged Pocket Guide, 36
 - EPA, *see* Eicosapentaenoic acid (EPA)
 - Exercise
 - acute vs. chronic effect, 117
 - beneficial effects, 113, 114

Exercise (*cont.*)

- benefits, specific populations
 - children, 116–117
 - older adults, 117
 - women, 115–116
- dose, 115
- guidelines, 123
- prescriptions, *see* Exercise prescriptions

Exercise associated collapse (EAC), 119

See also Exercise prescriptions

Exercise dose, 115

Exercise interventions, lipids and cardiovascular disease risk reduction, 113–127

Exercise prescriptions, 118

- estimating levels of exercise intensity
 - Heart Rate Reserve (HRR), 120–122
 - Rating of Perceived Exertion (RPE), 122
 - Borg's RPE Scale, 122
 - VO2 Reserve (VO2R), 120
- primary reason, 118
- special considerations, 125–126
- training progression
 - cardiorespiratory exercise, *see* Cardiorespiratory exercise, prescription
 - flexibility exercise prescription, 124–125
 - principles, overload/specificity, 118
 - resistance exercise prescription, 123–124
- training session organization
 - cool-down, 119–120
 - recreational activities, 119
 - stimulus or conditioning phase, 119
 - warm-up, 119

See also Exercise associated collapse (EAC)

F

FAAT, *see* Fatty Acid Antiarrhythmia Trial (FAAT)

Family issues, cardiovascular, 182

Fatty Acid Antiarrhythmia Trial (FAAT), 79

Fatty acids and sources, 55

Female athlete triad, 176–177

Fenugreek, 99–100

See also Therapeutic foods

Fibrates and niacin, 134

Fish oil and combination agents, 135

FITT principles (Frequency, Intensity, Type, Time), 118

Flavonoids, 84–85

- interleukin-2 (marker), 84
- subdivisions, 84–85

Folic acid, studies on

- Heart Outcomes Prevention Evaluation (HOPE) 2 Trial, 98
- Norwegian Vitamin (NORVIT) Trial, 98–99

See also Therapeutic foods

Framingham Heart Study, 113

G

Garlic, studies on, 93–94

See also Therapeutic foods

Gemfibrozil, 5

Genetic lipid disorders

- familial defective apolipoprotein B-100 (FDB), 30
- familial hypercholesterolemia (FH), 30
- polygenic hypercholesterolemia, 30

Geriatric prescription principles, 164–165

GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto), 48

Glycine max, 89

See also Soy protein

Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI), 76

H

Healthy Aging in Europe Longitudinal Study (HALE), 49

“Healthy fats,” 45

Heart Rate Reserve (HRR), 120–122

See also Exercise prescriptions

Helsinki Heart Study, 2

Hepatic toxicity, 153

Heterozygous FH, 31

High density lipoprotein cholesterol (HDL-C), 74

High Sensitivity-C-Reactive Protein (Hs-CRP), 188

- interpretation of, 187

See also Tools, risk assessment

Homocysteine, 189

See also Tools, risk assessment

Hs-CRP, *see* High Sensitivity-C-Reactive Protein (Hs-CRP)

Hyperlipidemia, drug treatment principles

- base intensity of drug therapy, accurate risk assessment, 131–132
- individual patient comorbidity assessment, 132–133
- initial dose to reach goal LDL, 132

- maximize monotherapy, before combination therapy, 132
- unique treatments requirements, special populations, 133
- Hyperlipidemia patients, practical approach
 - compliance and motivational tools, 195
 - patient education, 195
 - question/answer session, 195
 - reevaluation of risk/motivational talk, 195
 - referral guidelines, 199
 - sample lipid tracking card, 196
 - serum testing/patient follow-up frequency, 193–194
 - six-step approach, 197, 197–199
 - stepwise treatment plan, 195–199
- I**
- ICDs, *see* Implantable Cardiac Defibrillators (ICDs)
- Implantable Cardiac Defibrillators (ICDs), 79–80
- IMT, *see* Carotid Intimal Thickness (IMT)
- The Indian Study on Infarct Survival (ISIS), 76
- Intestinal transport proteins (ABCG5/ABCG8/NPC1L1), 74
- ISIS, *see* The Indian Study on Infarct Survival (ISIS)
- J**
- The Japan EPA Lipid Study (JELIS), 76–77
- JELIS, *see* The Japan EPA Lipid Study (JELIS)
- JUPITER trial, 187
- See also* Tools, risk assessment
- K**
- Key Adult Treatment Panel (ATP) III
 - findings/recommendations with evidence basis, 17
- L**
- LDL, *see* Low density lipoprotein
- LDL cholesterol, trials studying intensive reduction
 - ASTEROID trial of 2006, 7–8
 - Heart Protection Study (HPS), seminal 2002, 7
 - Incremental Decrease in End-Points Through Aggressive Lipid Lowering (IDEAL) Trial of 2005, 7
 - Infection- REVERSAL Trial of 2004, 7
 - Infection- Thrombolysis in Myocardial Infarction 22 Trial (PROVE IT-TIMI 22), 7
 - Intravascular Ultrasound Derived Coronary Atheroma Burden (ASTEROID) Trial of 2006, 7
 - 2004 Pravastatin/Atorvastatin Evaluation, Treat to New Targets (TNT) Trial of 2005, 7
 - See also* Low density lipoprotein
- Lecithin cholesterol acyltransferase (LCAT) promoters, 157
- Life habit risk factors, 21
- Lifestyle interventions, clinical recommendations, 64
- Lipid goals according to risk category, 197
- LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease), 3, 25, 166
- Lipid-lowering medications
 - side effects, 126
- Lipid Research Clinics Coronary Primary Prevention Cholestyramine Trial, 2
- Lipoprotein-a, 188
- See also* Tools, risk assessment
- Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), 188–198
- See also* Tools, risk assessment
- Low-carbohydrate diets
 - Atkins Diet, 40–41
 - cardiovascular risk factor endpoints
 - HDL cholesterol/triglycerides, 42–43
 - LDL cholesterol, 41–42
 - meta-analyses of, 43
- Low density lipoprotein, 1, 15, 29, 41, 74, 100, 113, 114, 133, 137, 162, 187, 188, 193
 - cholesterol goals and cutpoints for (TLC) and drug therapy in different risk categories, 26
 - cholesterol goals modifications, three categories of risk, 20
 - cholesterol/non-HDL cholesterol (C) goals for three risk categories, comparison, 32
 - reduction, initial statin dosages and percentage, 133
 - See also* LDL cholesterol, trials studying intensive reduction
- Low (very) fat diets, 43–45
- Ornish program, 44
- Lyons Diet Heart Study, 47
- M**
- Maximum heart rate (HRmax), 120
- formula, 120, 121
- See also* Exercise prescriptions

- Mediterranean diet
 experiments/results, 46–49
- Meta-analysis (2006), PROVE-IT/TNT/IDEAL/A to Z, 7
- Metabolic syndrome, 22–23, 26, 30, 33, 41, 42, 45, 58, 138, 156, 162, 170, 210, 216
- MIRACL Study, 2001, 5
- Moderate carbohydrate-high protein diets, 45–46
 South Beach Diet, 45
 Zone Diet, 45
- Monacolin K, 92
See also Went yeast
- Monounsaturated fatty acids (MUFA), 57
- Muscatine study, 2
- Myopathies, 144
 definitions, 151
 risk factors for statin-associated myopathy, 151, 152
- Myrrh, 100–101
- N**
- National cholesterol education program
 cost-effectiveness and risk assessment, 23–24
 drug therapy to achieve LDL cholesterol goals, 27–29
 bile acid sequestrants, consideration of, 28
 fibrate medications, 28–29
 for primary prevention, 29–30
 progression, 28
 for secondary prevention in hospitalized patients, 29
- LDL-lowering therapy in three risk categories, 25–26
- metabolic syndrome as secondary target of therapy
 causes, management of, 30
- 2004 NCEPATP-III update, 35–37
 modifications to ATP III recommendations, 36
 studies reviewed, 35–37
- primary prevention with LDL-lowering therapy, 24–25
 ATP recommendations, 24–25
- risk assessment, 16–23
- secondary prevention with LDL-lowering therapy, 25
 main studies (4S/CARE/LIPID studies), 25
- special issues
 adherence to LDL-lowering therapy, 34–35, 35
- diabetes mellitus, therapeutic options, 33
- different population groups, special considerations, 33–34
- elevated triglycerides, drug therapy schemes, 31–32
- HDL cholesterol, methods for raising the level, 32–33
- metabolic syndrome, management of causes, 30–31
 genetic lipid disorders, 30
- TLC in LDL-Lowering Therapy
 ATP III, recommendations, 26
medical nutrition therapy, 26
- National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III), 73
- National Cholesterol Education Program (NCEP), 2, 39, 46, 173, 188
- National Health and Nutrition Examination Survey (1999–2002), 39, 45, 56
- National Institute of Neurologic Disorders and Stroke (NINDS), 144
- Native Americans, cardiovascular issues, 174–175
- NCEP, *see* National Cholesterol Education Program (NCEP)
- NCEP/TLC/AHA dietary guidelines
 diet alone and cardiovascular risk factors, 51–52
 diet compliance, 53–54
 diet with supplementation, 54
 step 1/2 and cardiovascular outcomes, 53
 step 1/2 overview, 51
 with/without exercise, 52
- NCEP to TLC
 fatty acids, dietary fat impact on coronary risk and lipids, 55
 fruit and vegetable intake, 55–56
 therapeutic lifestyle changes, 57–58
- NHANES (National Health and Nutrition Examination Survey), 45
- Niacin, extended-release, 137, 155
- NINDS, *see* National Institute of Neurologic Disorders and Stroke (NINDS)
- Nonlipid risk factors, ATP III, 21
- NORVIT, *see* Norwegian Vitamin (NORVIT) Trial
- Norwegian Vitamin (NORVIT) Trial, 98–99
- Nutrient composition of therapeutic lifestyle changes (TLC) diet, 27
- Nuts, *see* Therapeutic foods

O

- Ocimum tenuiflorum*, *see* Basil
- Omega-3 Polyunsaturated Fatty Acids (PUFAs)
- AHA, recommendations for omega-3 fatty acid intake, 80, 83
 - antiarrhythmic effects, studies of, 78
 - Fatty Acid Antiarrhythmia Trial (FAAT), 79
 - patients, Implantable Cardiac Defibrillators (ICDs), 79–80
 - study on Omega-3 Fatty Acid and Ventricular Arrhythmia (SOFA), 78–79
 - cardiac outcomes and mortality, studies of, 76
 - conflicting studies, 78
 - Diet and Reinfarction Trial (DART), 77
 - Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI), 76
 - The Indian Study on Infarct Survival (ISIS), 76
 - The Japan EPA Lipid Study (JELIS), 76–77
 - meta-analyses, 77
 - physicians' health study, 77
 - EPA and DHA, sources, 75
 - lipid-lowering effects, studies of
 - flavonoids, sources, 84–85
 - See also* Therapeutic foods
 - Ornish, Dean, 44
 - Ornish program, 44
 - Oxygen uptake reserve (VO₂R), 120

P

- Pathobiologic Determinants of Atherosclerosis in Youth (PDAY), 2, 172, 204, 209
- Patient with multiple medical problems, hyperlipidemia prevention in
 - ASCVD, 179–180
 - ASPVD, 180
 - measures to consider, 179
 - renal disease, 181
 - See also* Special population, hyperlipidemia prevention
- PDAY, *see* Pathobiologic Determinants of Atherosclerosis in Youth (PDAY)
- Plant sterols and stanols
 - cholesterol-lowering benefit, 74
 - combination therapy, 73–74
 - See also* Therapeutic foods

- esterified forms, 74
- recommendations, AHA, 75
- Pleiotropic antiinflammatory effect of statins, 5
- Polypharmacy, 153
 - ten steps to reducing, 165
- Pre-statin trials
 - Cholesterol Lowering Atherosclerosis Study (CLAS), 2
 - Helsinki Heart Study, 2
 - Lipid Research Clinics Coronary Primary Prevention Cholestyramine Trial, 2
- Prevention strategies (hyperlipidemia) in elderly
 - older patients with CAD, evidence
 - heart protection study, 166
 - LIPID study, 166
 - Scandinavian Simvastatin Survival Study (4S), 166
 - PROSPER study, special nature, 169
 - stroke, 169
 - cost-effectiveness of therapy in elderly, 169–170
 - studies of geriatric age patients without CAD (primary prevention studies), evidence
 - AFCAPS/TEXCAPS study, 166–169
 - CARDS Trial, 169
 - See also* Special population, hyperlipidemia prevention
- Primary prevention statin trials of 1990s, 10
- Pritikin, Nathan, 44
- Protein (high) diets, *see* Moderate carbohydrate-high protein diets
- PROVE-IT trial, 187
 - See also* Tools, risk assessment
- PUFAs, *see* Omega-3 Polyunsaturated Fatty Acids (PUFAs)

R

- Rating of Perceived Exertion (RPE), 122
 - See also* Exercise prescriptions
- Red wine, *see* Therapeutic foods
- Resins and absorption inhibitors, 134
- Rhabdomyolysis, 177
 - See also* Elite athletes, hyperlipidemia prevention in
- Rimonabant in Obesity Trials, 157
- RIO trials, *see* Rimonabant in Obesity Trials
- Risk assessment
 - basics, 17–21
 - “core risk status,” 18
 - Framingham CHD risk score, calculation, 17–18

- Risk assessment (*Cont.*)
 metabolic syndrome, 22–23
 other risk factors, 21
 risk categories, 16
 Risk scoring system, benefits, 18
- S**
- Saturated fatty acid (SFA), 84
See also Chocolate; Therapeutic foods
- Scandinavian Simvastatin Survival Study (4S), 166
- Scavenger receptor class-B1 protein inhibitors (SR-B1), 157
- Screening/prevention issues, cardiovascular disease
 aspirin prophylaxis, 185–186
 novel screening tools for risk assessment, *see* Tools, risk assessment
- Seminal 2002 Heart Protection Study (HPS), 7
- Serum biomarkers, *see* Tools, risk assessment
- Serum lipid testing algorithm, 194
See also Hyperlipidemia patients, practical approach
- Six-step approach, hyperlipidemia, 197, 197–199
- SOFA, *see* Study on Omega-3 Fatty Acid and Ventricular Arrhythmia (SOFA)
- Solanum melongena* (egg plant), 101
See also Therapeutic foods
- Soluble fiber, 86–87
- South Beach Diet, 45, 46
See also Moderate carbohydrate-high protein diets
- Soy protein, 89–91
 AHA recommendations, 91–92
 background/studies, 90
 evolution of recommendations, 90–92
 isolated soy protein (ISP), 89
See also Therapeutic foods
- Special population, hyperlipidemia prevention
 adults below 35 years, 172–173
 children, 173–174
See also Children, hyperlipidemia prevention
 elders, 161–170
See also Prevention strategies (hyperlipidemia) in elderly
 elite athletes, 175–178
See also Elite athletes, hyperlipidemia prevention in
 family issues, 182
 native Americans, 174–175
See also Native Americans, cardiovascular issues
 patient with dementia, *see* Dementia patients (Alzheimer's/vascular/mixed dementia), hyperlipidemia prevention
 patient with multiple medical problems, 178–180
 women, 170–172
- Special populations, dietary interventions
 elderly, 49
 patients, hypercholesterolemia with/without statins, 50
 young women, 49
- Statins, 135
 Statin-associated myopathy, risk factors, 152
 Statin therapy, efficacy and safety
 primary prevention, evidence summary for, 10
 secondary prevention, evidence summary, 10–12
 AHA/ACC, guidelines for prevention, 11
 nondrug treatments, 11
- Statin trials
 efficacy and safety, *see* Statin therapy, efficacy and safety
 evidence summary, primary/secondary prevention, 10–12
 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMG-CoA reductase), 2–3
 major trials since 1999
 intensive reduction of LDL cholesterol, 5–8
 length, 8
 low HDL, 5
 MIRACL Study, 2001, 5
 pleiotropic antiinflammatory effect of statins, 5
 treatment during acute ischemia, 5
 primary prevention, 1990, 3
 secondary prevention, 1990s, 3–5
 CARE-1996, 5
 1990s (major), conceptual model, 7
 therapy, efficacy and safety, 10
 treatment, results of trials, 9
- Stretching programs, 124
See also Exercise prescriptions
- Study on Omega-3 Fatty Acid and Ventricular Arrhythmia (SOFA), 78–79
- “Super-statins,” 156

T

- Texturized vegetable protein (TVP), 89
 - See also* Soy protein
- TG, *see* Triglyceride (TG)
- Therapeutic foods, 102–103
 - Coenzyme Q10 (CoQ10), 96
 - dose, 87–88
 - eggplant, 101
 - fenugreek, 99–100
 - folic acid, 98–99
 - garlic, 93–94
 - holy basil, 102
 - myrrh, 100–101
 - nuts, 80
 - Omega-3 Polyunsaturated Fatty Acids (PUFAs), 75
 - plant sterols and stanols, 73–74
 - red wine and alcohol
 - biological mechanisms, alcohol and resveratrol, 88–89
 - dose, 87–88
 - red grape juice, 89
 - wine, 88
 - soluble fiber, studies on, 86
 - dietary recommendations, 87
 - soy protein, 89
 - and supplements associated with lipid lowering effects, recommendations, 81–83
 - vitamin E, 95
 - went yeast, 93
- Therapeutic lifestyle changes (TLC), 22, 25, 26, 36, 54, 57–58, 73, 118, 140, 171, 173, 182, 198, 202, 204, 208, 216
 - models of steps in, 27
- TLC, *see* Therapeutic lifestyle changes (TLC)
- Tools, risk assessment
 - serum biomarkers
 - Apolipoprotein A-1, 187–188
 - Apolipoprotein B, 188
 - B-Type Natriuretic Peptide (BNP), 189
 - High Sensitivity-C-Reactive Protein (Hs-CRP), 186–187
 - JUPITER trial, 187
 - PROVE-IT trial, 187
 - homocysteine, 189
 - Lipoprotein-a, 188
 - Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), 188–189
 - vascular imaging techniques
 - Carotid Intimal Thickness (IMT), 190

- Electron Beam Computed Tomography (EBCT)/Multislice CT Scanners, 189–190

- USPSTF recommendations, 190

- Total cholesterol level (TC), 113, 115, 116, 174, 175, 197

- Triglyceride (TG), 42, 90, 91, 100, 113–116, 123, 127, 132, 136, 137, 138, 141–144, 156–157, 175, 177, 193, 216, 217

- Trigonella foenum-graecum*, *see* Fenugreek

U

- United States Preventive Services Task Force, 185
- Upper limit of normal (ULN) creatinine kinase (CK) elevations, 144
- U.S. Preventive Services Task Force (USPSTF), 190
- USPSTF, *see* U.S. Preventive Services Task Force (USPSTF)

V

- Very low density lipoprotein (VLDL), 29, 41, 114, 137, 188
- Veterans Administration Study (VA-HIT), *see* Statin trials
- Vitamin E
 - mechanism, beneficial effects, 96
 - studies
 - Cambridge Heart Antioxidant Study (CHAOS), 95
 - See also* Therapeutic foods
- VO2 Reserve (VO2R), 120
 - See also* Exercise; Exercise prescriptions

W

- Weight training, 115
- Went Yeast
 - cholestin*®, 93
 - studies, 92–93
 - See also* Therapeutic foods
- Women
 - cardiovascular risk factor interventions, 171
 - hyperlipidemia prevention, 170–172
 - See also* Special population, hyperlipidemia prevention
 - “Work-out” phase, 119
 - See also* Exercise prescriptions
- 10-year risk estimation (Framingham Point Scores)
 - men, 20
 - women, 22